EIB Submits SEC Form 18-K/A Amendment No. 4: Unaudited Condensed Semi-Annual Financial Statements for Q2 2025

The European Investment Bank (EIB) has submitted SEC Form 18-K/A Amendment No. 4, which includes unaudited condensed semi-annual financial statements for the six-month period ended June 30, 2025. The document is available on the EIB website and the SEC's website.

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, reported its second-quarter 2025 financial results and significant pipeline developments. The company's cash position stands at $230 million, providing runway into H2 2027. Key developments include the completion of end-of-Phase 1 meetings with the FDA and EMA for lasme-cel (UCART22) in r/r B-ALL, with a pivotal Phase 2 launch planned for H2 2025. Financial highlights show consolidated revenues of $30.2 million for H1 2025, up from $16.0 million in H1 2024, primarily driven by a $20.0 million increase in AstraZeneca collaboration revenue. The company reported a net loss of $41.9 million ($0.42 per share) compared to $19.6 million ($0.24 per share) in the same period last year [1].

Pipeline progress includes ongoing Phase 1 study of eti-cel (UCART20x22) in r/r NHL with readout expected in late 2025, and advancement of three programs under the AstraZeneca partnership. A Servier arbitration decision is expected by December 15, 2025. Cellectis also announced an Investor R&D Day in New York City on October 16, 2025, where the company's leadership team and key opinion leaders will present the Phase 1 dataset and outline the late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL [1].

Revenue and expenses:
- Consolidated revenues and other income were $30.2 million for the six-month period ended June 30, 2025, compared to $16.0 million for the same period in 2024, reflecting a $14.2 million increase, primarily due to a $20.0 million increase in revenue from the AstraZeneca Joint Research Collaboration Agreement [1].
- Consolidated R&D expenses were $45.0 million for the six-month period ended June 30, 2025, compared to $45.8 million for the same period in 2024, down by $0.8 million [1].
- Consolidated SG&A expenses were $9.8 million for the six-month period ended June 30, 2025, compared to $9.0 million for the same period in 2024, up by $0.8 million [1].

Net financial gain (loss):
- The company reported a consolidated net financial loss of $18.1 million for the six-month period ended June 30, 2025, compared to an $18.0 million net financial gain for the same period in 2024, reflecting a $36.1 million difference [1].

Net income (loss) attributable to shareholders:
- Consolidated net loss attributable to shareholders of Cellectis was $41.9 million (or a $0.42 net loss per share) for the six-month period ended June 30, 2025, compared to a $19.6 million net loss (or a $0.24 net loss per share) for the same period in 2024, reflecting a $22.2 million change [1].

Adjusted net income (loss) attributable to shareholders:
- Consolidated adjusted net loss attributable to shareholders of Cellectis was $39.6 million (or a $0.40 loss per share) for the six-month period ended June 30, 2025, compared to a net loss of $17.9 million (or a $0.22 loss per share) for the same period in 2024, reflecting a $21.7 million change [1].

References:
[1] https://www.stocktitan.net/news/CLLS/cellectis-reports-second-quarter-2025-financial-results-business-6epx8vvbvt3o.html